Loading stock research
Loading stock research…
No token price observed
Observation time unavailableUnavailable
Underlying share reference$9.81(Jupiter stock data)
A reference quote for NTLA, not a price you can trade the token at.
Updated · Source: Jupiter stock data
Buy from your own wallet on Solana mainnet. You review and sign every transaction.
Checking whether mainnet purchases are available…
You sign in your own wallet. Ovelo never holds your keys or funds.
Daily closes of NTLA, the underlying share. A token’s rights, price and liquidity can differ from the share.
Research observed · Source: Yahoo Finance, Wikipedia (CC BY-SA)
What you would hold, where it trades and where these numbers come from.
Observation time unavailableUnavailable
The company behind NTLA.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Observed · Source: Company profile
Momentum from daily closes of the underlying share.
Computed from daily closes of the underlying share, not the token. Not a recommendation.
Close of · Source: Yahoo Finance daily closesStale
Reported financials. They describe the company, not the token’s market value.
| Item | Period end | Value |
|---|---|---|
| Revenue (annual) | 31 Dec 2025 | $67.67M |
| Revenue (annual) | 31 Dec 2024 | $57.88M |
| Revenue (annual) | 31 Dec 2023 | $36.28M |
| Revenue (annual) | 31 Dec 2022 | $52.12M |
| Net income (annual) | 31 Dec 2025 | −$412.69M |
| Net income (annual) | 31 Dec 2024 | −$519.02M |
| Net income (annual) | 31 Dec 2023 | −$481.19M |
| Net income (annual) | 31 Dec 2022 | −$474.19M |
| Diluted EPS (annual) | 31 Dec 2025 | −3.81 USD/share |
| Diluted EPS (annual) | 31 Dec 2024 | −5.25 USD/share |
| Diluted EPS (annual) | 31 Dec 2023 | −5.42 USD/share |
| Diluted EPS (annual) | 31 Dec 2022 | −6.16 USD/share |
| Total assets (annual) | 31 Dec 2025 | $842.13M |
| Total assets (annual) | 31 Dec 2024 | $1.19B |
| Total assets (annual) | 31 Dec 2023 | $1.30B |
| Total assets (annual) | 31 Dec 2022 | $1.52B |
| Total debt (annual) | 31 Dec 2025 | $93.33M |
| Total debt (annual) | 31 Dec 2024 | $210.20M |
| Total debt (annual) | 31 Dec 2023 | $115.35M |
| Total debt (annual) | 31 Dec 2022 | $130.70M |
| Operating cash flow (annual) | 31 Dec 2025 | −$394.74M |
| Operating cash flow (annual) | 31 Dec 2024 | −$348.88M |
| Operating cash flow (annual) | 31 Dec 2023 | −$394.09M |
| Operating cash flow (annual) | 31 Dec 2022 | −$333.29M |
| Free cash flow (annual) | 31 Dec 2025 | −$395.87M |
| Free cash flow (annual) | 31 Dec 2024 | −$354.66M |
| Free cash flow (annual) | 31 Dec 2023 | −$408.07M |
| Free cash flow (annual) | 31 Dec 2022 | −$391.68M |
| Revenue (quarterly) | 30 Sept 2026 | $7.16M |
| Revenue (quarterly) | 30 Jun 2026 | $7.66M |
| Revenue (quarterly) | 31 Mar 2026 | $15.05M |
| Revenue (quarterly) | 31 Dec 2025 | $23.02M |
| Revenue (quarterly) | 30 Sept 2025 | $13.78M |
| Net income (quarterly) | 30 Sept 2026 | −$127.49M |
| Net income (quarterly) | 30 Jun 2026 | −$106.63M |
| Net income (quarterly) | 31 Mar 2026 | −$96.23M |
| Net income (quarterly) | 31 Dec 2025 | −$95.79M |
| Net income (quarterly) | 30 Sept 2025 | −$101.32M |
| Diluted EPS (quarterly) | 30 Sept 2026 | −0.91 USD/share |
| Diluted EPS (quarterly) | 30 Jun 2026 | −0.80 USD/share |
| Diluted EPS (quarterly) | 31 Mar 2026 | −0.81 USD/share |
| Diluted EPS (quarterly) | 31 Dec 2025 | −0.83 USD/share |
| Diluted EPS (quarterly) | 30 Sept 2025 | −0.92 USD/share |
Reported dividends, splits and filings, each linked to its source.
No dividends, splits or filings were found.
Recent headlines about the company.